Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8899)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2019 (publication date) through Jul 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial. World J Gastroenterol 2019; 25(46): 6743-6751 [PMID: 31857776 DOI: 10.3748/wjg.v25.i46.6743] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i46/6743.htm |
| Number | Citing Articles |
| 1 |
June Hwa Bae, Hyeong Ho Jo, Joong Goo Kwon, Eun Young Kim. Efficacy of 7-day Tailored Therapy for Helicobacter pylori Eradication based on Clarithromycin Resistance. The Korean Journal of Gastroenterology 2023; 82(1): 10 doi: 10.4166/kjg.2023.039
|
| 2 |
Francis Megraud, Robin Bruyndonckx, Samuel Coenen, Linda Wittkop, Te-Din Huang, Martin Hoebeke, Lucie Bénéjat, Philippe Lehours, Herman Goossens, Youri Glupczynski. Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021; 70(10): 1815 doi: 10.1136/gutjnl-2021-324032
|
| 3 |
Yu Huang, Jinnan Chen, Zhaohui Ding, Xiao Liang, Hong Lu. Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2022; 37(7): 1212 doi: 10.1111/jgh.15864
|
| 4 |
Biao Guo, Nv-Wei Cao, Hao-Yue Zhou, Xiu-Jie Chu, Bao-Zhu Li. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microbial Pathogenesis 2021; 152: 104661 doi: 10.1016/j.micpath.2020.104661
|
| 5 |
Anthony O'Connor, Takahisa Furuta, Javier P. Gisbert, Colm O'Morain. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020; 25(S1) doi: 10.1111/hel.12743
|
| 6 |
Seung In Seo, Woon Geon Shin. Efficacy of Bismuth-based Quadruple Therapy as First-line Treatment for Clarithromycin-resistant Helicobacter pylori Infection. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2022; 22(3): 243 doi: 10.7704/kjhugr.2022.0025
|
| 7 |
Jun-Hyung Cho, So-Young Jin. Current guidelines for <i>Helicobacter pylori </i>treatment in East Asia 2022: Differences among China, Japan, and South Korea. World Journal of Clinical Cases 2022; 10(19): 6349-6359 doi: 10.12998/wjcc.v10.i19.6349
|
| 8 |
Su Jin Kim, Sam Ryong Jee, Moo In Park, Kyoungwon Jung, Gwang Ha Kim, Moon Won Lee, Jin Lee, Jin Seok Jang, Myeongseok Koh. A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations. Medicine 2022; 101(33): e30069 doi: 10.1097/MD.0000000000030069
|
| 9 |
Caiqi Liu, Yuan Wang, Jiaqi Shi, Chunhui Zhang, Jianhua Nie, Shun Li, Tongsen Zheng. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/1756284821989177
|
| 10 |
Hyungchul Park, Jeong Hoon Lee. Recent Trends in Tailored Treatments for Helicobacter pylori Infection. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(2): 115 doi: 10.7704/kjhugr.2021.0005
|
| 11 |
Youn I Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park. Tailored eradication strategy <i>vs</i> concomitant therapy for <i>Helicobacter pylori</i> eradication treatment in Korean patients. World Journal of Gastroenterology 2021; 27(31): 5247-5258 doi: 10.3748/wjg.v27.i31.5247
|
| 12 |
Jun-Hyung Cho, So Young Jin, Suyeon Park. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial. Expert Review of Anti-infective Therapy 2022; 20(6): 923 doi: 10.1080/14787210.2022.2017280
|
| 13 |
Olga P. Nyssen, Marta Espada, Javier P. Gisbert. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.913436
|
| 14 |
Seung In Seo, Hyun Lim, Chang Seok Bang, Young Joo Yang, Gwang Ho Baik, Sang Pyo Lee, Hyun Joo Jang, Sea Hyub Kae, Jinseob Kim, Hak Yang Kim, Woon Geon Shin. Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial. Gut and Liver 2022; 16(5): 697 doi: 10.5009/gnl210365
|
| 15 |
Kaihao Lin, Lifang Huang, Yadong Wang, Kangkang Li, Yuanning Ye, Siqi Yang, Aimin Li. Efficacy of genotypic susceptibility‐guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta‐analysis. Helicobacter 2023; 28(6) doi: 10.1111/hel.13015
|
| 16 |
Cailing Li, Kai Zhou, Baojun Suo, Yanyan Shi, Guangjie Ping, Liya Zhou, Zhiqiang Song.
Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment of
Helicobacter pylori
infection: a systematic review and meta-analysis
. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251348826
|
| 17 |
A Reum Choe, Ki-Nam Shim, Yehyun Park, Eun-Mi Song, Chung Hyun Tae, Sung-Ae Jung. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori Infection. Journal of Clinical Medicine 2021; 10(12): 2619 doi: 10.3390/jcm10122619
|
| 18 |
Theodore Rokkas, Konstantine Ekmektzoglou, David Y. Graham. Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta‐analysis and critical analysis. Helicobacter 2023; 28(1) doi: 10.1111/hel.12936
|
| 19 |
Ho-Yu Ng, Wai K. Leung, Ka-Shing Cheung. Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection. International Journal of Molecular Sciences 2023; 24(14): 11708 doi: 10.3390/ijms241411708
|
| 20 |
Javier P. Gisbert. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820968736
|
| 21 |
Erick A. Argueta, Steven F. Moss. Management of Helicobacter pylori. Current Opinion in Gastroenterology 2020; 36(6): 518 doi: 10.1097/MOG.0000000000000678
|
| 22 |
Sang Yoon Kim, Jae Myung Park, Chul-Hyun Lim, Hye Ah Lee, Ga-Yeong Shin, Younghee Choe, Yu Kyung Cho, Myung-Gyu Choi. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut and Liver 2021; 15(4): 528 doi: 10.5009/gnl20225
|